Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 48, 2008, Pages 18895-18900

  Louvet, Cédric ^a   Szot, Gregory L ^a   Lang, Jiena ^a   Lee, Michael R ^a   Martinier, Nicolas ^a   Bollag, Gideon ^b   Zhu, Shirley ^a   Weiss, Arthur ^a   Bluestone, Jeffrey A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PLEXXIKON INC   (United States)

Author keywords

Autoimmunity; Diabetes; Imatinib; PDGFR; Tyrosine kinase inhibitor

Indexed keywords

ABELSON KINASE; ARACHIS OIL; CYCLOPHOSPHAMIDE; IMATINIB; OKT 3; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PLX 647; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MONONUCLEAR CELL; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS ISLET CELL; PRIORITY JOURNAL; REMISSION; T LYMPHOCYTE; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INDOLES; LEUKOCYTES; MICE; MICE, INBRED NOD; MICE, SCID; PANCREAS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REMISSION INDUCTION;

MUS;

EID: 57749094961     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0810246105     Document Type: Article

References (49)

1. Druker BJ, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566.
2. Druker BJ, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417.
3. Buchdunger E, et al. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145.
4. Dewar AL, et al. (2005) Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105:3127-3132.
5. Guo J, et al. (2006) Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther 5:1007-1013.
6. Fabian MA, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329-336.
7. Joensuu H, Dimitrijevic S (2001) Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 33:451-455.
8. Pardanani A, et al. (2003) Imatinib for systemic mast-cell disease. Lancet 362:535-536.
9. Pardanani A, et al. (2003) Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood 101:3391-3397.
10. Boissel N, et al. (2004) Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 18:1656-1661.
11. Wolf AM, et al. (2005) The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci USA 102:13622-13627.
12. Dietz AB, et al. (2004) Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104:1094-1099.
13. Paniagua RT, et al. (2006) Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 116:2633-2642.
14. Koyama K, et al. (2007) Imatinib mesylate both prevents and treats the arthritis induced by type II collagen antibody in mice. Mod Rheumatol 17:306-310.
15. Sadanaga A, et al. (2005) Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum 52:3987-3996.
16. Miyachi K, et al. (2003) Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 22:329-332.
17. Eklund KK, Joensuu H (2003) Treatment of rheumatoid arthritis with imatinib mesylate: Clinical improvement in three refractory cases. Ann Med 35:362-367.
18. Miyagawa S, Fujimoto H, Ko S, Hirota S, Kitamura Y (2002) Improvement of psoriasis during imatinib therapy in a patient with ametastatic gastrointestinal stromal tumour. Br J Dermatol 147:406-407.
19. Eklund KK, Remitz A, Kautiainen H, Reitamo S, Leirisalo-Repo M (2006) Three months treatment of active spondyloarthritis with imatinib mesylate: An open-label pilot study with six patients. Rheumatology (Oxford) 45:1573-1575.
20. Magro F, Costa C (2006) Long-standing remission of Crohn's disease under imatinib therapy in a patient with Crohn's disease. Inflamm Bowel Dis 12:1087-1089.
21. Anderson MS, Bluestone JA (2005) The NOD mouse: A model of immune dysregulation. Annu Rev Immunol 23:447-485.
22. Hagerkvist R, Sandler S, Mokhtari D, Welsh N (2007) Amelioration of diabetes by imatinib mesylate (Gleevec): Role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 21:618-628.
23. Shoda LK, et al. (2005) A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23:115-126.
24. Seggewiss R, et al. (2005) Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 105:2473-2479.
25. Lieberman SM, et al. (2003) Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci USA 100:8384-8388.
26. Judkowski V, et al. (2001) Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J Immunol 166:908-917.
27. Tang Q, et al. (2006) Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 7:83-92.
28. Czechowicz A, Kraft D, Weissman IL, Bhattacharya D (2007) Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 318:1296-1299.
29. Murray LJ, et al. (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757-766.
30. Bour-Jordan H, et al. (2007) Constitutive expression of B7-1 on B cells uncovers autoimmunity toward the B cell compartment in the nonobese diabetic mouse. J Immunol 179:1004-1012.
31. Gu JJ, Zhang N, He YW, Koleske AJ, Pendergast AM (2007) Defective T cell development and function in the absence of abelson kinases. J Immunol 179:7334-7343.
32. Mumprecht S, Matter M, Pavelic V, Ochsenbein AF (2006) Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections. Blood 108:3406-3413.
33. Leder C, Ortler S, Seggewiss R, Einsele H, Wiendl H (2007) Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp Hematol 35:1266-1271.
34. Bocchia M, et al. (2005) Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia. Leukemia 20:142-143.
35. Chen CI, Maecker HT, Lee PP (2008) Development and dynamics of robust T cell responses to CML under imatinib treatment. Blood 111:5342-5349.
36. Appel S, et al. (2005) Effects of imatinib on monocyte-derived dendritic cells are mediated by inhibition of nuclear factor-kappaB and Akt signaling pathways. Clin Cancer Res 11:1928-1940.
37. Reinhardt RL, Hong S, Kang SJ, Wang ZE, Locksley RM (2006) Visualization of IL-12/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation. J Immunol 177:1618-1627.
38. Galli SJ, Grimbaldeston M, Tsai M (2008) Immunomodulatory mast cells: Negative, as well as positive, regulators of immunity. Nat Rev Immunol 8:478-486.
39. Sayed BA, Christy A, Quirion MR, Brown MA (2008) The master switch: The role of mast cells in autoimmunity and tolerance. Annu Rev Immunol 26:705-739.
40. Geoffrey R, et al. (2006) Evidence of a functional role for mast cells in the development of type 1 diabetes mellitus in the BioBreeding rat. J Immunol 177:7275-7286.
41. Karaman MW, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132.
42. Betsholtz C (2004) Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev 15:215-228.
43. Lewis EC, Shapiro L, Bowers OJ, Dinarello CA (2005) Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci USA 102:12153-12158.
44. Lu Y, et al. (2006) Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum Gene Ther 17:625-634.
45. Hagerkvist R, Makeeva N, Elliman S, Welsh N (2006) Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro. Cell Biol Int 30:1013-1017.
46. Ribeiro AL, et al. (2008) An evaluation of the cardiotoxicity of imatinib mesylate. Leuk Res 32:1809-1814.
47. Katz JD, Wang B, Haskins K, Benoist C, Mathis D (1993) Following a diabetogenic T cell from genesis through pathogenesis. Cell 74:1089-1100.
48. Herold KC, et al. (2005) A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54:1763-1769.
49. Chen W, et al. (2004) Insulin-like growth factor (IGF)-I/IGF-binding protein-3 complex: Therapeutic efficacy and mechanism of protection against type 1 diabetes. Endocrinology 145:627-638.